FI111222B - Menetelmä hybridi-alfa-interferoniliuoksen valmistamiseksi - Google Patents

Menetelmä hybridi-alfa-interferoniliuoksen valmistamiseksi Download PDF

Info

Publication number
FI111222B
FI111222B FI943705A FI943705A FI111222B FI 111222 B FI111222 B FI 111222B FI 943705 A FI943705 A FI 943705A FI 943705 A FI943705 A FI 943705A FI 111222 B FI111222 B FI 111222B
Authority
FI
Finland
Prior art keywords
interferon
hybrid
solution
weeks
concentration
Prior art date
Application number
FI943705A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943705A0 (fi
FI943705A (fi
Inventor
Nicholas Lowther
John Douglas Allen
Colin Howens
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939316849A external-priority patent/GB9316849D0/en
Priority claimed from GB9405879A external-priority patent/GB9405879D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI943705A0 publication Critical patent/FI943705A0/fi
Publication of FI943705A publication Critical patent/FI943705A/fi
Application granted granted Critical
Publication of FI111222B publication Critical patent/FI111222B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
FI943705A 1993-08-13 1994-08-10 Menetelmä hybridi-alfa-interferoniliuoksen valmistamiseksi FI111222B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9316849 1993-08-13
GB939316849A GB9316849D0 (en) 1993-08-13 1993-08-13 Pharmaceutical compositions
GB9405879A GB9405879D0 (en) 1994-03-24 1994-03-24 Pharmaceutical compositions
GB9405879 1994-03-24

Publications (3)

Publication Number Publication Date
FI943705A0 FI943705A0 (fi) 1994-08-10
FI943705A FI943705A (fi) 1995-02-14
FI111222B true FI111222B (fi) 2003-06-30

Family

ID=26303371

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943705A FI111222B (fi) 1993-08-13 1994-08-10 Menetelmä hybridi-alfa-interferoniliuoksen valmistamiseksi

Country Status (19)

Country Link
US (1) US5609868A (ko)
EP (1) EP0641567B1 (ko)
JP (1) JP3745395B2 (ko)
KR (1) KR100351495B1 (ko)
AT (1) ATE190498T1 (ko)
AU (1) AU679233B2 (ko)
CA (1) CA2129921C (ko)
CY (1) CY2230B1 (ko)
DE (1) DE69423402T2 (ko)
DK (1) DK0641567T3 (ko)
ES (1) ES2144034T3 (ko)
FI (1) FI111222B (ko)
GR (1) GR3033239T3 (ko)
HU (1) HU224613B1 (ko)
IL (1) IL110566A (ko)
NO (1) NO315843B1 (ko)
NZ (1) NZ264218A (ko)
PT (1) PT641567E (ko)
TW (1) TW249202B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102236A1 (en) * 1994-12-08 2002-08-01 Taylor Peter William Liposomal interferon hybrid compositions
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
KR20000069664A (ko) * 1996-12-24 2000-11-25 아스트루 마이클 제이 안정한 액체 인터페론 제제
KR19990075253A (ko) * 1998-03-18 1999-10-15 성재갑 약학적으로 안정한 인터페론 제
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
ES2167189B1 (es) * 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
HU228583B1 (en) 2000-11-07 2013-04-29 Novartis Vaccines & Diagnostic Stabilized interferon compositions
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CA2613737C (en) * 2005-06-29 2017-05-23 Yeda Research And Development Co. Ltd. Recombinant interferon .alpha.2 (ifn.alpha.2) mutants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196823A (ja) * 1983-04-20 1984-11-08 Sunstar Inc 皮膚および粘膜の真菌症治療用外用剤
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
FI861193A (fi) * 1985-03-25 1986-09-26 Schering Corp Stabilt gammainterferonpreparat.
EP0205404B1 (en) * 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer

Also Published As

Publication number Publication date
PT641567E (pt) 2000-08-31
KR100351495B1 (ko) 2003-02-19
FI943705A0 (fi) 1994-08-10
FI943705A (fi) 1995-02-14
DK0641567T3 (da) 2000-08-14
IL110566A0 (en) 1995-01-24
CA2129921C (en) 2006-12-05
ATE190498T1 (de) 2000-04-15
HU9402356D0 (en) 1994-10-28
DE69423402D1 (de) 2000-04-20
AU6893994A (en) 1995-02-23
JP3745395B2 (ja) 2006-02-15
NO942983L (no) 1995-02-14
ES2144034T3 (es) 2000-06-01
CA2129921A1 (en) 1995-02-14
NO942983D0 (no) 1994-08-12
AU679233B2 (en) 1997-06-26
TW249202B (ko) 1995-06-11
NZ264218A (en) 1995-07-26
CY2230B1 (en) 2003-04-18
JPH07145070A (ja) 1995-06-06
DE69423402T2 (de) 2000-08-03
NO315843B1 (no) 2003-11-03
GR3033239T3 (en) 2000-09-29
KR950005325A (ko) 1995-03-20
IL110566A (en) 1999-12-22
EP0641567A1 (en) 1995-03-08
EP0641567B1 (en) 2000-03-15
HU224613B1 (hu) 2005-11-28
US5609868A (en) 1997-03-11
HUT68692A (en) 1995-07-28

Similar Documents

Publication Publication Date Title
JP7441892B2 (ja) ペグ化ブタインターフェロンおよびその使用方法
FI95002C (fi) Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi
JP4988562B2 (ja) 安定化したインターフェロン液体製剤
US7173008B2 (en) Lyophilized HGF preparations
FI91884B (fi) Menetelmä yhdistelmägammainterferonin valmistamiseksi, jolla on parannettu stabiilisuus, ja menetelmässä käytetty vektori ja DNA
FI111222B (fi) Menetelmä hybridi-alfa-interferoniliuoksen valmistamiseksi
UA80331C2 (en) Human serum albumin-free stabilised interferon liquid formulations
HU202883B (en) Process for producing and purifying alpha interferon
Le et al. Purification and properties of a novel recombinant human hybrid interferon, σ-4 α2/α1
KR101191536B1 (ko) 안정화된 인터페론 액상 제제

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG